David Ubben

David Ubben

Auto-generated profile, based on publicly available information

David Ubben

Medicines for Malaria Venture (MMV), Geneva, Switzerland

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2012 in Malaria Journal
Verified
Journal Article
Open access
PDF file
UDUmberto D'Alessandro
Umberto D'Alessandro
DUDavid Ubben
David Ubben
KHKamal Hamed
Kamal Hamed
SCSerign Jawo Ceesay
Serign Jawo Ceesay
JOJoseph Okebe
Joseph Okebe
BBBernard Brabin
Bernard Brabin
Despite the protection provided by several factors, including maternal antibodies, the burden of malaria in young infants may be higher than previously thought. Infants with congenital or neonatal malaria may have a different clinical presentation than older children, and diagnosis may be confused with other neonatal diseases due to an overlap of clinical manifestations. In addition, there is little information on the use of artemisinin-based combination therapy in young infants. There is the need for a more accurate estimate of the parasite prevalence and the incidence of clinical malaria in infants under 6 months old, as well as a better characterization of risk factors, pharmacokinetic profiles, safety and efficacy of currently available anti-malarial treatments, in order to develop evidence-based treatment guidelines for this population.

22 August 2012 in Malaria Journal
Verified
Journal Article
Open access
PDF file
XDXavier C Ding
Xavier C Ding
DUDavid Ubben
David Ubben
TWTimothy N. C Wells
Timothy N. C Wells
Resistance is a constant challenge for anti-infective drug development. Since they kill sensitive organisms, anti-infective agents are bound to exert an evolutionary pressure toward the emergence and spread of resistance mechanisms, if such resistance can arise by stochastic mutation events. New classes of medicines under development must be designed or selected to stay ahead in this vicious circle of resistance control. This involves both circumventing existing resistance mechanisms and selecting molecules which are resilient against the development and spread of resistance. Cell-based screening methods have led to a renaissance of new classes of anti-malarial medicines, offering us the potential to select and modify molecules based on their resistance potential. To that end, a standardized in vitro methodology to assess quantitatively these characteristics in Plasmodium falciparum during the early phases of the drug development process has been developed and is presented here. It allows the identification of anti-malarial compounds with overt resistance risks and the prioritization of the most robust ones. The integration of this strategy in later stages of development, registration, and deployment is also discussed.

29 July 2011 in Malaria Journal
Verified
Journal Article
Open access
PDF file
SKSteven E Kern
Steven E Kern
ATAlfred B Tiono
Alfred B Tiono
MMMichael Makanga
Michael Makanga
AGAdama Dodji Gbadoé
Adama Dodji Gbadoé
ZPZulfiqarali Premji
Zulfiqarali Premji
BOBernhards Ogutu
Bernhards Ogutu
Asymptomatic carriers of Plasmodium falciparum serve as a reservoir of parasites for malaria transmission. Identification and treatment of asymptomatic carriers within a region may reduce the parasite reservoir and influence malaria transmission in that area.

22 January 2010 in Malaria Journal
Verified
Journal Article
Open access
PDF file
BOBernhards Ogutu
Bernhards Ogutu
ATAlfred B Tiono
Alfred B Tiono
MMMichael Makanga
Michael Makanga
ZPZulfiqarali Premji
Zulfiqarali Premji
AGAdama Dodji Gbadoé
Adama Dodji Gbadoé
OGOumar Gaye
Oumar Gaye
Increased investment and commitment to malaria prevention and treatment strategies across Africa has produced impressive reductions in the incidence of this disease. Nevertheless, it is clear that further interventions will be necessary to meet the international target of a reversal in the incidence of malaria by 2015. This article discusses the prospective role of an innovative malaria control strategy - the community-based treatment of asymptomatic carriers of Plasmodium falciparum, with artemisinin-based combination therapy (ACT). The potential of this intervention was considered by key scientists in the field at an Advisory Board meeting held in Basel, in April 2009. This article summarizes the discussions that took place among the participants.

28 February 2011 in Malaria Journal
Verified
Journal Article
Open access
PDF file
MNMichael Nambozi
Michael Nambozi
Jean-Pierre Van GeertruydenJean-Pierre Van Geertruyden
Jean-Pierre Van Geertruyden
SHSebastian Hachizovu
Sebastian Hachizovu
MCMike Chaponda
Mike Chaponda
DMDoreen Mukwamataba
Doreen Mukwamataba
UDUmberto D'Alessandro
Umberto D'Alessandro
Malaria in Zambia remains a public health and developmental challenge, affecting mostly children under five and pregnant women. In 2002, the first-line treatment for uncomplicated malaria was changed to artemether-lumefantrine (AL) that has proved to be highly efficacious against multidrug resistant Plasmodium falciparum. The study objective was to determine whether dihydroartemisinin-piperaquine (DHA/PQP) had similar efficacy, safety and tolerability as AL for the treatment of children with uncomplicated P. falciparum malaria in Ndola, Zambia. Between 2005 and 2006, 304 children (6-59 months old) with uncomplicated P. falciparum were enrolled, randomized to AL (101) or DHA/PQP (203) and followed up for 42 days. Outcome of treatment was defined according to the standard WHO classification, i.e. early treatment failure (ETF), late clinical failure (LCF, late parasitological failure (LPF) and adequate clinical and parasitological response (ACPR). Recurrent infections were genotyped to distinguish between recrudescence and new infection. No ETF was observed. At day 28, PCR-uncorrected ACPR was 92% in the DHA/PQP and 74% in the AL arm (OR: 4.05; 95%CI: 1.89-8.74; p < 0.001). Most failure were new infections and PCR-corrected ACPR was similar in the two study arms (OR: 0.69; 95%CI: 0.22-2.26; p = 0.33). Similar results were observed for day 42, i.e. higher PCR-uncorrected ACPR for DHA/PQP, mainly due to the difference observed up to day 28, while the PCR-corrected ACPR was similar: DHA/PQP: 93% (179/192), AL: 93% (84/90), (OR: 0.92; 95%CI: 0.30-2.64; p = 0.85). Except for cough, more frequent in the DHA/PQP arm (p = 0.04), there were no differences between treatment arms in the occurrence of adverse events. Two serious adverse events were probably associated to AL treatment. DHA/PQP was as efficacious, safe and well tolerated in treatment of uncomplicated malaria as AL, though in the latter group more new infections during the follow up were observed. DHA/PQP seems a potential candidate to be used as an alternative first-line or rescue treatment in Zambia. ISRCTN16263443, at http://www.controlled-trials.com/isrctn

6 December 2010 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
MMMayfong Mayxay
Mayfong Mayxay
SKSommay Keomany
Sommay Keomany
MKManiphone Khanthavong
Maniphone Khanthavong
PSPhoutthalavanh Souvannasing
Phoutthalavanh Souvannasing
KSKasia Stepniewska
Kasia Stepniewska
PNPaul Newton
Paul Newton
We conducted an open, randomized clinical trial of oral dihydroartemisinin-piperaquine (DP) versus artesunate-mefloquine (AM) in 300 patients in Laos with uncomplicated Plasmodium falciparum malaria as part of a multicentre study in Asia. Survival analysis and adjustment for re-infection showed that the 63-day cure rates (95% confidence interval [CI]) were 100% for AM and 99.5% (96.4–99.8%) for DP. The 63-day cure rates per protocol were 99% (97 of 98) for AM and 99.5% (196 of 197) for DP (P = 0.55). The difference (AM minus DP) in cure rates (95% CI) was −0.5% (−5.1 to 2.0%), which is within the 5% non-inferiority margin. The median fever and parasite clearance times were also similar for AM and DP. The proportion of patients with at least one recorded potential adverse event was significantly higher in the AM group (38 of 87, 44%) than in the DP group (57 of 182, 31%) (relative risk = 0.6, 95% CI = 0.4–0.9; P = 0.04). Dihydroartemisinin-piperaquine is not inferior to AM in the treatment of uncomplicated P. falciparum malaria in Laos and is associated with fewer adverse effects. The results of this study were similar to those of the larger multicentre study.